Skip to main content
Grant Details

Grant Number: 1U54CA260582-01 Interpret this number
Primary Investigator: Oltz, Eugene
Organization: Ohio State University
Project Title: Center for Serological Testing to Improve Outcomes From Pandemic COVID-19 (Stop-COVID)
Fiscal Year: 2020


Abstract

Overall Project Summary Stemming the spread of COVID-19 will require research that cross-cuts basic, translational, and applied sciences. The Center for Serological Testing to Improve Outcomes from Pandemic COVID-19 (STOP- COVID) is proposed as a transdisciplinary entity to understand the interface between exposure risk, transmission, immune responses, disease severity, protection, and barriers to testing/vaccination, with the goal of improving population health and clinical outcomes. The Center will utilize state-of-the-art serological and molecular tests, developed at OSU, in a longitudinal study of first responders, a group at continual high risk of SARS-CoV-2 exposure, as well as their household contacts. Through the proposed work, STOP-COVID investigators will understand critical aspects of: (i) transmission in both asymptomatic and symptomatic individuals, (ii) immune, host, and viral determinants of disease outcome, and (iii) factors associated with immune protection. Center investigators will also identify best practices for communication of test results and information about COVID-19 to improve understanding of risk, transmission, and protection, while reducing access barriers to testing. The Center to STOP-COVID will: Aim 1 Develop Institute Infrastructure through three shared resource cores: 1. An Administrative Core that provides overall direction and leadership, coordinating all Center activities as well as Project–Core–SeroNet interactions; 2. A Testing and Biorepository Core, whose role is to perform first-tier serologic and viral testing during our longitudinal study using high throughput ELISA and neutralization assays developed at OSU, and cost-shared by OSU; and 3. A Data Management and Analysis Core that will provide project investigators with a centralized resource for biostatistics, bioinformatics, epidemiology, and psychometrics expertise. Aim 2: Conduct three innovative research projects to address: Project 1: Parallel serological and viral testing to determine COVID-19 prevalence, transmission, and protection in extended first responder cohorts. This project will also generate serology data for vaccines or mAbs, once available to this presumably high-priority group; Project 2: Serologic and molecular determinants of COVID-19 severity and immune protection. This project will evaluate COVID-19 serological responses in the context of SARS-CoV-2 and common cold CoV (CCCoV) antibodies, using novel assays specific for a panel of antigens. Project 2 also will employ transcriptomics to understand how host genetics, CCCoV, other respiratory viruses, and immune responses contribute to pathogenesis; and Project 3: Responding to changing serological and viral information around COVID-19. This project will incorporate results from Projects 1 & 2 and SeroNet to inform best practices in risk communication, provide behavioral guidance to decrease transmission, and enhance protection from disease. Aim 3: SeroNet Participation and Sharing of Data and Best Practices. We will leverage STOP-COVID infrastructure to share data, results, reagents, and best practices with SeroNet, which will drive new discoveries and their translation into actionable strategies for implementation across all groups affected by COVID-19.



Publications

The COVID-19 vaccine concerns scale: Development and validation of a new measure.
Authors: Gregory M.E. , MacEwan S.R. , Powell J.R. , Volney J. , Kurth J.D. , Kenah E. , Panchal A.R. , McAlearney A.S. .
Source: Human vaccines & immunotherapeutics, 2022-11-30; 18(5), p. 2050105.
EPub date: 2022-04-05.
PMID: 35380510
Related Citations

Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2.
Authors: Evans J.P. , Zeng C. , Qu P. , Faraone J. , Zheng Y.M. , Carlin C. , Bednash J.S. , Zhou T. , Lozanski G. , Mallampalli R. , et al. .
Source: Cell host & microbe, 2022-08-10; 30(8), p. 1093-1102.e3.
EPub date: 2022-04-25.
PMID: 35526534
Related Citations

Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection.
Authors: Cui Z. , Zeng C. , Huang F. , Yuan F. , Yan J. , Zhao Y. , Zhou Y. , Hankey W. , Jin V.X. , Huang J. , et al. .
Source: Nature chemical biology, 2022-07-25; , .
EPub date: 2022-07-25.
PMID: 35879545
Related Citations

Durability of the Neutralizing Antibody Response to mRNA Booster Vaccination Against SARS-CoV-2 BA.2.12.1 and BA.4/5 Variants.
Authors: Qu P. , Faraone J.N. , Evans J.P. , Zheng Y.M. , Carlin C. , Lozanski G. , Saif L.J. , Oltz E.M. , Gumina R.J. , Liu S.L. .
Source: bioRxiv : the preprint server for biology, 2022-07-22; , .
EPub date: 2022-07-22.
PMID: 35898337
Related Citations

Respiratory mucosal immunity against SARS-CoV-2 following mRNA vaccination.
Authors: Tang J. , Zeng C. , Cox T.M. , Li C. , Son Y.M. , Cheon I.S. , Wu Y. , Behl S. , Taylor J.J. , Chakraborty R. , et al. .
Source: Science immunology, 2022-07-19; , p. eadd4853.
EPub date: 2022-07-19.
PMID: 35857583
Related Citations

Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants.
Authors: Qu P. , Faraone J. , Evans J.P. , Zou X. , Zheng Y.M. , Carlin C. , Bednash J.S. , Lozanski G. , Mallampalli R.K. , Saif L.J. , et al. .
Source: The New England journal of medicine, 2022-06-30; 386(26), p. 2526-2528.
EPub date: 2022-06-15.
PMID: 35704428
Related Citations

COVID-19 Booster Uptake among First Responders and Their Household Members May Be Lower than Anticipated.
Authors: Frey J.A. , Bachmann D.J. , Anghelina M. , Sircelj V. , Saadoon O. , Stevens P. , Pietrzak M. , Fernández S. , McAlearney A.S. , Panchal A.R. .
Source: Vaccines, 2022-06-24; 10(7), .
EPub date: 2022-06-24.
PMID: 35891175
Related Citations

Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants.
Authors: Evans J.P. , Qu P. , Zeng C. , Zheng Y.M. , Carlin C. , Bednash J.S. , Lozanski G. , Mallampalli R.K. , Saif L.J. , Oltz E.M. , et al. .
Source: The New England journal of medicine, 2022-06-16; 386(24), p. 2340-2342.
EPub date: 2022-05-18.
PMID: 35584183
Related Citations

Pandemic Experience of First Responders: Fear, Frustration, and Stress.
Authors: McAlearney A.S. , Gaughan A.A. , MacEwan S.R. , Gregory M.E. , Rush L.J. , Volney J. , Panchal A.R. .
Source: International journal of environmental research and public health, 2022-04-13; 19(8), .
EPub date: 2022-04-13.
PMID: 35457559
Related Citations

Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection.
Authors: Evans J.P. , Zeng C. , Carlin C. , Lozanski G. , Saif L.J. , Oltz E.M. , Gumina R.J. , Liu S.L. .
Source: Science translational medicine, 2022-03-23; 14(637), p. eabn8057.
EPub date: 2022-03-23.
PMID: 35166573
Related Citations

The Serological Sciences Network (SeroNet) for COVID-19: Depth and Breadth of Serology Assays and Plans for Assay Harmonization.
Authors: Karger A.B. , Brien J.D. , Christen J.M. , Dhakal S. , Kemp T.J. , Klein S.L. , Pinto L.A. , Premkumar L. , Roback J.D. , Binder R.A. , et al. .
Source: medRxiv : the preprint server for health sciences, 2022-03-14; , .
EPub date: 2022-03-14.
PMID: 35262095
Related Citations

An Opportunity to Understand Concerns about COVID-19 Vaccination: Perspectives from EMS Professionals.
Authors: MacEwan S.R. , Gaughan A.A. , Gregory M.E. , Rush L.J. , Powell J.R. , Kurth J.D. , Panchal A.R. , McAlearney A.S. .
Source: Vaccines, 2022-03-02; 10(3), .
EPub date: 2022-03-02.
PMID: 35335012
Related Citations

Closing the Gap on COVID-19 Vaccinations in First Responders and Beyond: Increasing Trust.
Authors: Gregory M.E. , MacEwan S.R. , Gaughan A.A. , Rush L.J. , Powell J.R. , Kurth J.D. , Kenah E. , Panchal A.R. , Scheck McAlearney A. .
Source: International journal of environmental research and public health, 2022-01-06; 19(2), .
EPub date: 2022-01-06.
PMID: 35055463
Related Citations

SARS-CoV-2 spreads through cell-to-cell transmission.
Authors: Zeng C. , Evans J.P. , King T. , Zheng Y.M. , Oltz E.M. , Whelan S.P.J. , Saif L.J. , Peeples M.E. , Liu S.L. .
Source: Proceedings of the National Academy of Sciences of the United States of America, 2022-01-04; 119(1), .
PMID: 34937699
Related Citations

Neutralization and Stability of SARS-CoV-2 Omicron Variant.
Authors: Zeng C. , Evans J.P. , Qu P. , Faraone J. , Zheng Y.M. , Carlin C. , Bednash J.S. , Zhou T. , Lozanski G. , Mallampalli R. , et al. .
Source: bioRxiv : the preprint server for biology, 2021-12-20; , .
EPub date: 2021-12-20.
PMID: 34981053
Related Citations

Loss of Neutralizing Antibody Response to mRNA Vaccination against SARS-CoV-2 Variants: Differing Kinetics and Strong Boosting by Breakthrough Infection.
Authors: Evans J.P. , Zeng C. , Carlin C. , Lozanski G. , Saif L.J. , Oltz E.M. , Gumina R.J. , Liu S.L. .
Source: bioRxiv : the preprint server for biology, 2021-12-07; , .
EPub date: 2021-12-07.
PMID: 34909777
Related Citations

Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients.
Authors: Zeng C. , Evans J.P. , Reisinger S. , Woyach J. , Liscynesky C. , Boghdadly Z.E. , Rubinstein M.P. , Chakravarthy K. , Saif L. , Oltz E.M. , et al. .
Source: Cell & bioscience, 2021-11-21; 11(1), p. 197.
EPub date: 2021-11-21.
PMID: 34802457
Related Citations

COVID-19 Vaccinations in EMS Professionals: Prevalence and Predictors.
Authors: Gregory M.E. , Powell J.R. , MacEwan S.R. , Kurth J.D. , Kenah E. , Panchal A.R. , McAlearney A.S. .
Source: Prehospital emergency care, 2021-11-03; , p. 1-9.
EPub date: 2021-11-03.
PMID: 34644239
Related Citations

Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H.
Authors: Zeng C. , Evans J.P. , Faraone J.N. , Qu P. , Zheng Y.M. , Saif L. , Oltz E.M. , Lozanski G. , Gumina R.J. , Liu S.L. .
Source: mBio, 2021-10-26; 12(5), p. e0251021.
EPub date: 2021-10-05.
PMID: 34607452
Related Citations

Inhibition of elastase enhances the adjuvanticity of alum and promotes anti-SARS-CoV-2 systemic and mucosal immunity.
Authors: Kim E. , Attia Z. , Woodfint R.M. , Zeng C. , Kim S.H. , Steiner H.E. , Shukla R.K. , Liyanage N.P.M. , Ghimire S. , Li J. , et al. .
Source: Proceedings of the National Academy of Sciences of the United States of America, 2021-08-24; 118(34), .
PMID: 34353890
Related Citations

Role of host factors in SARS-CoV-2 entry.
Authors: Evans J.P. , Liu S.L. .
Source: The Journal of biological chemistry, 2021 07; 297(1), p. 100847.
EPub date: 2021-05-28.
PMID: 34058196
Related Citations

SARS-CoV-2 Spreads through Cell-to-Cell Transmission.
Authors: Zeng C. , Evans J.P. , King T. , Zheng Y.M. , Oltz E.M. , Whelan S.P.J. , Saif L. , Peeples M.E. , Liu S.L. .
Source: bioRxiv : the preprint server for biology, 2021-06-01; , .
EPub date: 2021-06-01.
PMID: 34100011
Related Citations

A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike.
Authors: Lu M. , Dravid P. , Zhang Y. , Trivedi S. , Li A. , Harder O. , Kc M. , Chaiwatpongsakorn S. , Zani A. , Kenney A. , et al. .
Source: Proceedings of the National Academy of Sciences of the United States of America, 2021-03-23; 118(12), .
PMID: 33688034
Related Citations

Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors.
Authors: Zeng C. , Evans J.P. , Pearson R. , Qu P. , Zheng Y.M. , Robinson R.T. , Hall-Stoodley L. , Yount J. , Pannu S. , Mallampalli R.K. , et al. .
Source: JCI insight, 2020-11-19; 5(22), .
EPub date: 2020-11-19.
PMID: 33035201
Related Citations




Back to Top